Company intelligence / Profile preview

Kimia Therapeutics

Berkeley, California, United Stateskimiatx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Kimia Therapeutics has not yet reported clinical results. The company focuses on preclinical drug discovery using its proprietary ATLAS platform to generate and screen novel small molecule compounds targeting a broad range of diseases including cancer, immunological, and inflammatory disorders. No clinical candidates or trial outcomes have been announced as of May 2025. [4][5][8]

Therapeutic areas: OncologyImmunology
Modalities: Small moleculesNovel chemical libraries
Industry: Biotech

Partnerships

Carmot Therapeutics (collaboration on metabolic programs)

Beyond the preview

Go deeper on Kimia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kimia Therapeutics.

Explore the full profile